Recent Finacing
Recent Raise
Tobira Therapeutics is a clinical-stage biopharma developing dual CCR2/CCR5 antagonists (cenicriviroc, TBR-652) to treat NASH-related fibrogenesis and CCR5-tropic HIV, advancing candidates through Phase II trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors